RAGUSA, FRANCESCA
 Distribuzione geografica
Continente #
NA - Nord America 5.169
AS - Asia 2.502
EU - Europa 2.175
SA - Sud America 502
Continente sconosciuto - Info sul continente non disponibili 358
AF - Africa 143
OC - Oceania 9
Totale 10.858
Nazione #
US - Stati Uniti d'America 5.025
IT - Italia 919
SG - Singapore 774
CN - Cina 655
BR - Brasile 410
HK - Hong Kong 391
SE - Svezia 361
VN - Vietnam 284
DE - Germania 191
FR - Francia 114
BG - Bulgaria 110
GB - Regno Unito 109
FI - Finlandia 86
CA - Canada 84
RU - Federazione Russa 81
IN - India 67
NL - Olanda 59
IQ - Iraq 52
JP - Giappone 49
TR - Turchia 44
CI - Costa d'Avorio 41
BD - Bangladesh 40
MX - Messico 33
AR - Argentina 28
PL - Polonia 27
AT - Austria 23
SN - Senegal 22
NG - Nigeria 21
KR - Corea 20
ZA - Sudafrica 20
ES - Italia 18
EC - Ecuador 17
ID - Indonesia 16
CO - Colombia 15
SA - Arabia Saudita 15
CH - Svizzera 13
UA - Ucraina 13
PH - Filippine 12
MA - Marocco 11
UZ - Uzbekistan 10
CZ - Repubblica Ceca 9
PK - Pakistan 9
PY - Paraguay 9
VE - Venezuela 9
IE - Irlanda 8
AU - Australia 7
JO - Giordania 7
KE - Kenya 7
LT - Lituania 7
UY - Uruguay 7
AE - Emirati Arabi Uniti 6
BY - Bielorussia 5
IL - Israele 5
IR - Iran 5
KZ - Kazakistan 5
AL - Albania 4
BE - Belgio 4
GT - Guatemala 4
HN - Honduras 4
MY - Malesia 4
PS - Palestinian Territory 4
TH - Thailandia 4
TN - Tunisia 4
BB - Barbados 3
CL - Cile 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
EG - Egitto 3
GR - Grecia 3
JM - Giamaica 3
NP - Nepal 3
OM - Oman 3
RO - Romania 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
BH - Bahrain 2
BJ - Benin 2
BN - Brunei Darussalam 2
BS - Bahamas 2
DK - Danimarca 2
ET - Etiopia 2
EU - Europa 2
GE - Georgia 2
GY - Guiana 2
PE - Perù 2
RS - Serbia 2
AM - Armenia 1
BW - Botswana 1
CY - Cipro 1
EE - Estonia 1
FJ - Figi 1
GA - Gabon 1
GH - Ghana 1
HR - Croazia 1
KG - Kirghizistan 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
Totale 10.491
Città #
Ashburn 619
Dallas 526
Singapore 463
Fairfield 400
Santa Clara 392
San Jose 383
Hong Kong 380
Milan 210
Woodbridge 206
Pisa 191
Chandler 179
Seattle 174
Shanghai 174
Council Bluffs 151
Cambridge 149
Houston 145
Wilmington 132
Serra 127
Los Angeles 117
New York 113
Sofia 110
Beijing 91
Munich 78
Boardman 74
Ho Chi Minh City 73
Princeton 72
Ann Arbor 58
Helsinki 53
Florence 49
London 49
Lauterbourg 47
Rome 47
Lawrence 46
Tokyo 45
Frankfurt am Main 42
Medford 42
Abidjan 41
Hanoi 39
Hefei 35
Redondo Beach 33
Buffalo 32
São Paulo 32
Dong Ket 27
Boulder 26
Turku 24
Redwood City 23
San Diego 23
Dakar 22
Columbus 21
Istanbul 21
Paris 21
Warsaw 21
Bremen 20
Ottawa 20
Seoul 20
Des Moines 19
Fuzhou 19
Lagos 18
Nuremberg 18
Sulaymaniyah 18
Chicago 17
Phoenix 17
Baghdad 16
Montreal 16
Nanjing 16
Ogden 16
Amsterdam 15
Livorno 15
Vienna 15
Rio de Janeiro 14
Brooklyn 13
Carrara 13
Washington 13
Chennai 12
Da Nang 12
Dearborn 12
Denver 12
Johannesburg 12
Orem 12
Toronto 12
Brasília 11
Norwalk 11
The Dalles 11
Baltimore 10
Changsha 10
Düsseldorf 10
Guangzhou 10
Haiphong 10
Hyderabad 10
Manchester 10
Memphis 9
Quanzhou 9
Tashkent 9
Zurich 9
Cascina 8
Dhaka 8
Dublin 8
Figino 8
Mexico City 8
Amman 7
Totale 7.266
Nome #
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 256
Hashimotos’ thyroiditis: Epidemiology, pathogenesis, clinic and therapy 253
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 242
Molecular testing in the diagnosis of differentiated thyroid carcinomas 229
Sunitinib in the treatment of thyroid cancer 225
The aggregation between AITD with rheumatologic, or dermatologic, autoimmune diseases 211
Oral L-thyroxine liquid versus tablet in patients submitted to total thyroidectomy for thyroid cancer (without malabsorption): A prospective study 203
Cytokines as Targets of Novel Therapies for Graves’ Ophthalmopathy 198
THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors 196
New insight in endocrine-related adverse events associated to immune checkpoint blockade 195
Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer 193
Novel therapies for thyroid autoimmune diseases: An update 192
Graves’ disease: Epidemiology, genetic and environmental risk factors and viruses 190
Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture 188
Induction of Th1 chemokine secretion in dermal fibroblasts by vanadium pentoxide 186
Myo-inositol in autoimmune thyroiditis, and hypothyroidism 184
Novel treatments for anaplastic thyroid carcinoma 178
Differential modulation by vanadium pentoxide of the secretion of CXCL8 and CXCL11 chemokines in thyroid cells 168
The association of other autoimmune diseases in patients with Graves’ disease (with or without ophthalmopathy): Review of the literature and report of a large series 168
The Stability of TSH, and Thyroid Hormones, in Patients Treated With Tablet, or Liquid Levo-Thyroxine 168
Vanadium pentoxide induces the secretion of CXCL9 and CXCL10 chemokines in thyroid cells 165
Immunomodulation of CXCL10 secretion by hepatitis C virus: Could CXCL10 be a prognostic marker of chronic hepatitis C? 165
Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy 164
Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update 162
Novel treatment options for anaplastic thyroid cancer 162
Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration 162
Immune and inflammatory cells in thyroid cancer microenvironment 162
Chemokines in thyroid autoimmunity 161
Nutraceuticals in thyroidology: A review of in vitro, and in vivo animal studies 159
Thyroid Autoimmunity and SARS-CoV-2 Infection 155
Recent advances in precision medicine for the treatment of anaplastic thyroid cancer 155
Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer 154
CXCL8 and CXCL11 chemokine secretion in dermal fibroblasts is differentially modulated by vanadium pentoxide 154
Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies 154
Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin 153
Precision Medicine in Autoimmune Thyroiditis and Hypothyroidism 151
Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN-ALK Fusion In Vitro 150
Antineoplastic effect of doxorubizen in vitro in continuous and primary human anaplastic thyroid cancer cells 147
The protective effect of myo-inositol on human thyrocytes 147
Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy 147
Lactose intolerance and levothyroxine malabsorption: a review of the literature and report of a series of patients treated with liquid L-T4 without lactose 145
Hypothyroidism and metabolic cardiovascular disease 145
Chemokines in hyperthyroidism 143
Autoimmune endocrine dysfunctions associated with cancer immunotherapies 142
Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer 140
Liquid L-T4 therapy in hypothyroid patients with gastric diseases, an observational study 139
Molecular features of aggressive thyroid cancer 139
Molecular targets of tyrosine kinase inhibitors in thyroid cancer 139
Circulating CXCL10 is increased in non-segmental vitiligo, in presence or absence of autoimmune thyroiditis 136
Thyroid Metastasis from Primary Breast Cancer 133
Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases 126
Graves' disease induced by IFN-β1a therapy: A case report, review of literature and new insights into the pathogenesis 123
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 122
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 121
Simultaneous Occurrence of Medullary Thyroid Carcinoma and Papillary Thyroid Carcinoma: A Case Series with Literature Review 118
Teprotumumab for the treatment of thyroid eye disease 115
null 115
Precision Medicine in Graves’ Disease and Ophthalmopathy 115
Endocrine disruptors and thyroid autoimmunity 106
L-T4 Therapy in Enteric Malabsorptive Disorders 106
Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies 104
Evaluating vandetanib in the treatment of medullary thyroid cancer: Patient-reported outcomes 104
Thyroid autoimmunity and SARS-CoV-2 infection: Report of a large Italian series 103
Thyroid autoimmune disorders and cancer 90
Graves' Disease Following SARS-CoV-2 Vaccination: A Systematic Review 87
null 87
Myoinositol in Autoimmune Thyroiditis 76
null 75
Th1 chemokines in autoimmune endocrine disorders 70
Psoriasis, Psoriatic Arthritis, and Thyroid Autoimmunity 44
The pyrazolo[3,4-d]pyrimidine derivative CLM24 has an antineoplastic effect in aggressive dedifferentiated thyroid cancer in vitro 42
Autoimmune Thyroid Diseases and Epigenetics 33
Dermatomyositis and MIG 33
MIG chemokine in systemic sclerosis. MIG in Systemic sclerosis 30
Mesothelioma and interferon-γ-dependent chemokine IP-10 28
Nanoparticles in Thyroid Autoimmunity: Diagnostic and Therapeutic Applications 27
IP-10 in occupational asthma: review of the literature and case-control study 27
Th1 chemokines in ulcerative colitis 27
Sarcoidosis and the Th1 chemokine MIG 26
Sarcoidosis and Th1 chemokines 25
Totale 10.858
Categoria #
all - tutte 32.595
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.595


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022702 0 14 28 47 109 92 32 33 67 59 56 165
2022/2023770 118 106 67 37 68 92 34 46 122 5 62 13
2023/2024836 67 78 121 97 120 135 55 24 12 17 38 72
2024/20252.627 119 72 72 140 259 310 257 124 149 283 307 535
2025/20263.722 259 386 556 376 314 261 522 168 200 399 107 174
2026/2027302 139 163 0 0 0 0 0 0 0 0 0 0
Totale 10.858